Organogenesis Holdings Inc is a leading regenerative medicine company that focuses on developing and commercializing advanced wound care and surgical biologics products
The company specializes in innovative solutions that support the healing of complex wounds and surgical procedures, leveraging its expertise in cellular and tissue-based therapies. Organogenesis is committed to improving patient outcomes by offering cutting-edge products that foster healing and recovery, thereby addressing unmet medical needs in the healthcare sector. Through a combination of research, development, and clinical support, the company aims to enhance the quality of care provided to patients across various medical disciplines.
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
San Diego, CA -- (SBWIRE) -- 04/22/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Organogenesis Holdings Inc.
Robbins Geller Rudman & Dowd LLP announces that purchasers of Organogenesis Holdings Inc. (NASDAQORGO) securities between March 17, 2021 and October 11, 2021, inclusive (the “Class Period”) have until this upcoming Tuesday, February 8, 2022 to seek appointment as lead plaintiff in Somogyi v. Organogenesis Holdings Inc., No. 21-cv-06845 (E.D.N.Y.). Commenced on December 10, 2021, the Organogenesis class action lawsuit charges Organogenesis along with certain of its top executives with violations of the Securities Exchange Act of 1934.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Organogenesis Holdings Inc. (“Organogenesis”) (NASDAQORGO). The action charges Organogenesis with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Organogenesis’s materially misleading statements to the public, Organogenesis’s investors have suffered significant losses.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Organogenesis Holdings, Inc. (“Organogenesis” or the “Company”) (NASDAQORGO) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Organogenesis securities between March 17, 2021 and October 11, 2021, both dates inclusive (the “Class Period”). Investors have until February 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQORGO) securities between March 17, 2021 and October 11, 2021, inclusive (the “Class Period”).
Los Angeles - (NewMediaWire) - February 03, 2022 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against Organogenesis
Holdings Inc. (“Organogenesis” or “the Company”) (NASDAQORGO) for violations of §§10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
San Diego, CA -- (SBWIRE) -- 02/01/2022 -- The Shareholders Foundation announced that a deadline is coming up on February 8, 2022 in the lawsuit filed for certain investors of Organogenesis Holdings Inc. (NASDAQORGO).
